Fonte L, Fernández ACM

Language: Spanish
References: 14
Page: 1-4
PDF size: 253.61 Kb.

Text Extraction

No abstract.

REFERENCES

1. World Health Organization. Coronavirus press conference, 11 February 2020. Geneva: WHO; 2020. [acceso: 18/07/2021]. Disponible en: https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-full-press-conference-11feb 2020-final.pdf?sfvrsn=e2019136_2]

2. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi. 2021;7:298. DOI: https://doi.org/10.3390/jof7040298]

3. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20:269-70. DOI: https://doi.org/10.1038/s41577-020-0308-3]

4. Fonte L, Acosta A, Sarmiento ME, Ginori M, García G, Norazmi MN. COVID 19 lethality in Sub-Saharan Africa and helminth immune modulation. Front Immunol. 2020;11. DOI: https://doi.org/10.3389/fimmu.2020.574910]

5. Szarpak L, Chirico F, Pruc M, Szarpak L, Dzieciatkowski T, Rafique Z. Mucormycosis-A serious threat in the COVID-19 pandemic? J Infect. 2021;83:237-79. DOI: https://doi.org/10.1016/j.jinf.2021.05.015]

6. Johnson A, Ghazarian Z, Cendrowski K, Persichino J. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep. 2021;32:64-7. DOI: https://doi.org/10.1016/j.mmcr.2021.03.006]

7. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL,et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-53. DOI: https://doi.org/10.1086/432579]

8. Ibrahim A, Spellberg B, Walsh T, Kontoyiannis D. Pathogenesis of Mucormycosis. Clin Infect Dis. 2012;54:16-22. DOI: https://doi.org/10.1093/cid/cir865]

9. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556-69. DOI: http://dx.doi.org/10.1128/CMR.18.3.556-569.2005]

10. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;135:442-7. DOI: https://doi.org/10.1017/S0022215121000992]

11. Jose A, Singh S, Roychoudhury A, Kholakiya Y, Arya S, Roychoudhury S. Current understanding in the pathophysiology of SARS-CoV-2- associated rhino-orbito-cerebral mucormycosis: a comprehensive review. J Maxillofac Oral Surg. 2021;20:373-80. DOI: https://doi.org/10.1007/s12663-021-01604-2]

12. Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: An Update. J Fungi. 2020;6:265. DOI: https://doi.org/10.3390/jof6040265]

13. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr Clin Res Rev. 2021;15:102146. DOI: http://doi.org/10.1016/j.dsx.2021.05.019]

14. World Health Organization. WHO Coronavirus (COVID-19) Dashboard, 16 July 2021. Geneva: WHO; 2021. [acceso: 18/07/2021]. Disponible en: https://covid19.who.int/]